OBJECTIVE To compare and contrast the efficacy and safety of patiromer and sodium zirconium cyclosilicate (ZS-9) in the treatment of hyperkalemia. DESIGN A systematic review and meta-analysis of phase II and III clinical trial data was completed. PATIENTS OR PARTICIPANTS Eight studies (two phase II and four phase III trials with two subgroup analyses) were included in the qualitative analysis, and six studies (two phase II and four phase III trials) were included in the meta-analysis. MEASUREMENTS AND RESULTS Significant heterogeneity was found in the meta-analysis with an I 2 value ranging from 80.6-99.6%. A random-effects meta-analysis was applied for all end points. Each clinical trial stratified results by hyperkalemia severity and dosing; therefore, these were considered separate treatment groups in the meta-analysis. For patiromer, a significant À0.70 mEq/L (95% confidence interval [CI] À0.48 to À0.91 mEq/L) change was noted in potassium at 4 weeks. At day 3 of patiromer treatment, potassium change was À0.36 mEq/L (range of standard deviation 0.07-0.30). The primary end point for ZS-9-change in potassium at 48 hours-was À0.67 mEq/L (95% CI À0.45 to À0.89 mEq/L). By 1 hour after ZS-9 administration, change in potassium was À0.17 mEq/L (95% CI À0.05 to À0.30). Analysis of pooled adverse effects from these trials indicates that patiromer was associated with more gastrointestinal upset (7.6% constipation, 4.5% diarrhea) and electrolyte depletion (7.1% hypomagnesemia), whereas ZS-9 was associated with the adverse effects of urinary tract infections (1.1%) and edema (0.9%). CONCLUSION Patiromer and ZS-9 represent significant pharmacologic advancements in the treatment of hyperkalemia. Both agents exhibited statistically and clinically significant reductions in potassium for the primary end point of this meta-analysis. Given the adverse effect profile and the observed time-dependent effects, ZS-9 may play more of a role in treating acute hyperkalemia. KEY WORDS hyperkalemia, patiromer, sodium zirconium cyclosilicate, ZS-9, sodium polystyrene sulfonate.
adverse effects and ambiguous efficacy. [1] [2] [3] [4] [5] [6] [7] To date, the single randomized clinical trial that evaluated SPS for hyperkalemia demonstrated a limited evidence base for the safety and efficacy of currently available therapies. 8 In addition, patients at high risk for hyperkalemia are often those with disease states such as heart failure and chronic kidney disease (CKD) that derive great benefit from renin-angiotensin-aldosterone system (RAAS) inhibitors. This drug class is a major source of drug-induced hyperkalemia. [9] [10] [11] [12] [13] Management of hyperkalemia in these patient populations often includes reduction or discontinuation of RAAS inhibitors that may have a negative impact on outcomes. Thus there is a significant gap in the current treatment armamentarium for hyperkalemia.
Patiromer calcium sorbitex (patiromer) and sodium zirconium cyclosilicate (ZS-9) seek to fill the hyperkalemia treatment gap and overcome limitations of available therapies. These new oral agents are nonabsorbed polymers that bind potassium in the gastrointestinal (GI) tract and facilitate fecal potassium removal from the body. Patiromer is marketed under the brand name Veltassa and was approved by the U.S. Food and Drug Administration (FDA) in October 2015.
14 Given its onset of 7-48 hours, patiromer was approved for chronic management of hyperkalemia and carries a warning that the drug is not to be administered for emergency management of severe hyperkalemia. Alternatively, ZS-9 has a more rapid onset of 1-6 hours and is not currently FDA approved. In May 2016, the manufacturer announced that the FDA had issued a Complete Response Letter regarding the New Drug Application because of initial FDA concerns about preapproval manufacturing inspections.
Clinical trials for both patiromer and ZS-9 appear to provide evidence for efficacy in lowering potassium. Despite enrollment of several hundred patients per trial, the individual treatment groups had small numbers of patients because of stratification by hyperkalemia severity and dose administered. These small groups included varying patient populations and different underlying comorbidities across studies. Thus the purpose of this systematic review and meta-analysis was to determine treatment effect estimates for patiromer and ZS-9 at critical times postdose from all available phase II and phase III clinical trials. This goal of this approach is to allow for a more robust comparison between these new agents.
Methods

Study Design
This systematic review and meta-analysis was conducted according to a standardized prespecified protocol and reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 15 All phase II and III clinical trials of patiromer or ZS-9 published in English were considered for inclusion in the systematic review. The minimum follow-up period was 4 weeks for patiromer and 48 hours for ZS-9 based on the pharmacology of each drug and the design of major clinical trials. Placebo control was not an eligibility criterion, given the open-label nature of the initial phase of most clinical trials (most trials deemed an initial placebo control to be unethical among patients with known hyperkalemia).
Literature Search and Selection
PubMed, Embase, and Web of Science databases were queried for literature that included the terms "patiromer" or "Veltassa" or "sodium zirconium cyclosilicate" or "ZS-9" or "ZS9" or "SZC" from inception to July 1, 2016. References of selected studies were reviewed for additional literature.
Titles and abstracts of literature search results were independently screened by two authors and filtered for phase II and III clinical trials. Studies were selected based on the eligibility criteria defined earlier.
Data Extraction
Two end points were selected for each drug based on their pharmacologic characteristics and the available clinical trial end points. The end points were patiromer change in potassium at 4 weeks of treatment and change in potassium at study day 3. For ZS-9, the end points were a change in potassium at 48 hours of treatment and a change in potassium at 1 hour. Data were also collected regarding the frequency of patients maintained in the normal potassium range (defined by each study: 3.5-5.0 mEq/L, 16 21 ) throughout the followup period and the frequency of patients able to maintain, initiate, or titrate RAAS inhibitors. Safety data were also collected for each drug. Data were extracted from each study by reviewing the published study, appendices, and supplemental data. Data collection was done using a standardized database and completed independently by two authors.
Risk of bias was assessed according to the Cochrane Collaboration's tool for assessing risk of bias in randomized trials. 22 
Statistical Analysis
Treatment effects were defined as a change in serum potassium concentration from baseline. Summary measures for these continuous end points were mean differences and their associated 95% CIs. Based on available data, an estimate of the mean difference and range of standard deviation (SD) were assessed for the secondary end point of patiromer. The summary measures were compared between study groups as defined by the severity of hyperkalemia (e.g., mild vs moderate) and the dose of medication in that study arm. This stratification provided important differentiation between the severity of hyperkalemia that is clinically relevant and provides interpretation of the dose response for each drug. Frequency and percentage of maintenance of normokalemia, use of RAAS inhibitors, and adverse effects were collated from each study and pooled into an aggregate occurrence rate.
Between-study heterogeneity was assessed using the I 2 statistic. 23 Given high heterogeneity (I 2 higher than 75%), a random-effects meta-analysis was applied to all end points because the random-effects method assumes heterogeneity exists across all studies. 24 A sensitivity analysis was conducted using a fixed-effects model.
All tests were 2-tailed with a nominal level of significance set at less than 0.05. R statistical software was used for analysis (Vienna, Austria; https://www.R-project.org). Figure 1 displays the study selection process. Three clinical trials each were included in the meta-analysis for patiromer (654 subjects) 20, 21, 25 and ZS-9 (1102 subjects). [17] [18] [19] Two additional studies were included in the qualitative analysis for ZS-9 because the results were subgroup analyses or analyses of data combined from the other clinical trials. 26, 27 Baseline characteristics for patients in the patiromer trials were a mean age of 65.8 years, mean serum potassium of 5.31 mEq/L, and a mean estimated glomerular filtration rate (eGFR) of 45.1 ml/minute/1.73 m 2 . Among the patiromer patients, 93% had CKD, 73% had type 2 diabetes mellitus, 48% had heart failure, and 86% were receiving concomitant RAAS inhibitor therapy. The ZS-9 trials had similar baseline characteristics: the mean age was 65.7 years, mean serum potassium was 5.35 mEq/L, and mean eGFR was 45.8 ml/minute/1.73 m 2 . However, compared with the patiromer trials there was a lower prevalence of CKD (66%), type 2 diabetes mellitus (61%), heart failure (39%), and concomitant use of a RAAS inhibitor (67%) in the ZS-9 trials.
Results
Study Characteristics
Risk of Bias and Study Heterogeneity
Three studies 18, 19, 25 had a 86% low risk of bias (14% unclear risk), two studies 17, 20 had a 57% high risk of bias (29% low risk, 14% unclear risk), and one study 21 had a 43% high risk of bias (29% low risk, 29% unclear risk). Most of the high risk of bias was derived from the open-label nature of the initial phase of these studies. There was a low risk of outcomelevel bias in all studies.
All six of the studies in the meta-analysis showed significant heterogeneity, with an I 2 estimate ranging from 80.6-99.6%. This level of heterogeneity could be explained by differences in patient populations, underlying comorbidities, study design, and effect estimates.
Treatment Outcomes
Three clinical trials, including nine prespecified subgroups, were included for patiromer (Table 1) . 20, 21, 25 The primary end point of this meta-analysis, change in potassium at 4 weeks, was À0.70 mEq/L (95% CI À0.48 to À0.91 mEq/L; 603 subjects) using a randomeffects meta-analysis (Figure 2A ). The secondary end point, change in potassium at 3 days, was À0.36 mEq/L (range of SD 0.07-30 mEq/L; Figure 2B ) using random-effects meta-analysis. Among 110 patients, 93% were able to maintain, initiate, or titrate a RAAS inhibitor during maintenance phases of the studies. 21, 25 In addition, during the maintenance phases, 74-95% of patients were maintained in the normal potassium range. 20, 21, 25 Three clinical trials that included seven prespecified subgroups were included for ZS-9 (Table 1) . [17] [18] [19] The primary end point, change in potassium at 48 hours, was À0.67 mEq/L (95% CI À0.45 to À0.89 mEq/L; 760 subjects) by random-effects meta-analysis ( Figure 3A) . In a subgroup analysis of patients with heart failure, the mean change in potassium at 48 hours was À1.2 mEq/L following ZS-9 dosed at 10 g 3 times/day. 26 The secondary end point, change in potassium at 1 hour, was À0.17 mEq/L (95% CI À0.05 to À0.30 mEq/L; Figure 3B ) by randomeffects meta-analysis. A subanalysis of 45 patients with severe hyperkalemia (baseline serum potassium 6.1-7.2 mEq/L) showed a reduction in potassium of À0.4 mEq/L (95% CI À0.2 to À0.5 mEq/L) at 1 hour following a 10-g dose of ZS-9. 27 In the one trial, 71-85% of patients were maintained in the normal potassium range by the end of the 4-week randomized phase. 17 No trial reported the number of patients able to maintain, titrate, or initiate RAAS inhibitor therapy. Table 2 displays the pooled clinical trial results of the most common adverse effects. [17] [18] [19] [20] [21] 25 GI adverse effects and electrolyte abnormalities were most common in patiromer-treated patients. No serious GI effects occurred in any patient on patiromer or ZS-9. Discontinuation of therapy due to an adverse effect occurred in 8% (43/538) of patients on patiromer and 1% (5/479) of patients on ZS-9 during the maintenance phases of the trials.
Adverse Effects
Discussion
In this systematic review and meta-analysis, patiromer and ZS-9 exhibited consistent and clinically relevant reductions in serum potassium among at-risk patient populations. Each agent appears to have a favorable short-term safety profile from available data. The diversity among At the screening phase, records were excluded because they were not evaluative studies of patiromer or sodium zirconium cyclosilicate (e.g., editorial, review, commentary, etc.), not conducted in humans, or not published in English. Intervention Multidose ZS-9 Maintenance study; K = potassium; OPAL-HK = two-part single-blind phase III study evaluating the efficacy and safety of patiromer for the treatment of hyperkalemia; PEARL-HF = evaluation of patiromer in heart failure patients; ZS-9 = sodium zirconium cyclosilicate.
a These two studies were not included in the quantitative analysis given that their data are derived from the phase III trials of ZS-9 already included in the meta-analysis.
the study quality was predominantly the result of an open-label initial treatment phase.
In this study, patiromer demonstrated a significant reduction in potassium at 3 days and 4 weeks of treatment by random-effects metaanalysis. These results were confirmed by a sensitivity analysis with a fixed-effects model (Figure 2 ). This finding is consistent with current product labeling for the use of patiromer in the maintenance of normokalemia. The degree of potassium reduction may depend on the severity of baseline hyperkalemia. The effect of . AMETHYST-DN = effect of patiromer in the treatment of hyperkalemia and diabetic nephropathy; OPAL-HK = two-part single-blind phase III study evaluating the efficacy and safety of patiromer for the treatment of hyperkalemia PEARL-HF = evaluation of patiromer in heart failure patients.
patiromer in the treatment of hyperkalemia and diabetic nephropathy (AMETHYST-DN) trial showed a greater reduction in potassium in patients with moderate hyperkalemia (À0.97 mEq/L) compared with mild hyperkalemia (À0.55 mEq/L; Figure 2A ) despite receiving the same daily dose of patiromer (12.6 g). 20 The patiromer clinical trials demonstrated consistent efficacy through 12-and 52-week follow-up periods, although the 52-week period was open label and not placebo controlled. 20, 21 Normokalemia was maintained in 77-95% of follow-up visits over 52 weeks, 20 and RAAS inhibitor therapy was able to be continued in 94% of patiromer-treated patients after 12 weeks. 21 The major caveat to these data is that twice/day patiromer dosing was utilized in these trials, whereas the FDA-approved dose is once/day. This change stemmed from concern over the drug interaction potential of patiromer. In addition, a phase I trial showed that fecal potassium excretion was similar between patiromer regimens dosed at 8.4 g 3 times/day (1550 AE 519 mg), 12.6 g twice/day (1419 AE 550 mg), and 25.2 g once/day (1283 AE 530 mg; p= 0.37). 28 Confirmatory postmarketing studies are warranted. There is a concern regarding drug-drug interactions because patiromer has the potential to bind other Figure 3 . Meta-analysis results for sodium zirconium cyclosilicate (ZS-9) clinical trials. These forest plots indicate the mean difference (black box) with 95% confidence interval (horizontal bars) for the meta-analysis effect estimates. Change in potassium at 48 hours was the primary end point shown in panel A and had a heterogeneity of I 2 = 98.3%. The secondary end point was change in potassium at 1 hour with a heterogeneity of I 2 = 80.6%. HARMONIZE = hyperkalemia randomized intervention multidose ZS-9 maintenance study; TID = 3 times/day. medication in the GI tract based on in vitro binding studies. 14, 29 Although not an exhaustive list, medications that have shown a reduction in bioavailability when coadministered with patiromer include trimethoprim, clopidogrel, amlodipine, cinacalcet, metoprolol, furosemide, levothyroxine, metformin, and ciprofloxacin (Veltassa [Patiromer] for Oral Suspension: Drug-Drug Interactions, written communication, 2016). Other medications must be separated from patiromer administration by at least 3 hours according to updated recommendations from November 2016. This unwieldly administration schedule may have an impact on adherence in a patient population likely to be on multiple medications. Patiromer was also studied for the treatment of acute hyperkalemia with a mean potassium reduction of À0.21 mEq/L and a 7-hour onset of action. 16 These results demonstrated that it is not advisable to use patiromer for acute management of hyperkalemia. 14 GI-adverse effects were more common with patiromer than ZS-9 (Table 2) , likely the result of sorbitol in the patiromer formulation. However, a 8.4-g dose of patiromer contains~4 g sorbitol, compared with 20 g sorbitol in a 15-g dose of SPS. 30 No severe GI-adverse effects were observed in the 660 patients in the safety analysis. Given the rare occurrence of these events with SPS, a larger sample size is necessary to rule out serious GI-adverse effects such as intestinal necrosis with patiromer. Hypomagnesemia occurred in 7.1% of patients on patiromer, reflective of its nonselective nature for the potassium ion. More frequent laboratory monitoring of magnesium concentrations and patient education regarding the symptoms of hypomagnesemia (muscle weakness/cramping, nystagmus, and numbness) are warranted. Hypomagnesemia can be managed with oral supplementation, but it should not be administered within 3 hours of patiromer. Caution should be used when lowering the potassium concentration in patients with heart failure and/or CKD because values lower than 4.0 mEq/L may be associated with increased mortality. 31, 32 Hypokalemia occurred in 4.7% of patients receiving patiromer, but these studies defined hypokalemia as a potassium concentration lower than 3.5 mEq/ L. 20, 21, 25 This study demonstrated that ZS-9 exhibits a quick and reliable reduction in potassium. With an onset of 1 hour, ZS-9 may play a more significant role in the treatment of acute hyperkalemia than patiromer. The meta-analysis effect estimate for potassium reduction at 1 hour was À0.17 mEq/L, but data were only available from five of the seven treatment groups ( Figure 3B ). The clinical significance of this finding is unknown because a potassium reduction of À0.17 mEq/L may not translate to clinically apparent effects. However, in a separate analysis of the phase III trials, 17, 19 52% of patients reached a potassium of 5.5 mEq/L or lower within 4 hours, and the mean potassium reduction was À0.4 mEq/L at 1 hour that is greater than our meta-analysis effect estimate. 27 This difference could be because the analysis was of a small Data displayed as n (%). HARMONIZE = Hyperkalemia Randomized Intervention Multidose ZS-9 Maintenance study; NR = not reported; OPAL-HK = two-part singleblind phase III study evaluating the efficacy and safety of patiromer for the treatment of hyperkalemia; ZS-9 = sodium zirconium cyclosilicate. Trials with multiple phases were considered separate for purposes of pooling adverse event data. 17, 19, 21 For example, in OPAL-HK, 243 patients were in the initial phase and 107 (55 on patiromer) were in the randomized phase. Therefore, this trial contributed 298 patients to analysis of pooled adverse events for patiromer. subgroup (45 subjects) that had severe hyperkalemia (potassium 6.1-7.2 mEq/L) treated with 10 g ZS-9, whereas our meta-analysis included 0.3-, 3-, and 10-g doses with a baseline potassium of 5.35 mEq/L. There may also be a potassium concentration dependent efficacy, whereby the higher baseline serum potassium concentration leads to a more pronounced potassium-lowering effect (Table 3) . Although SPS has long been the only FDA-approved potassium removal agent available, its use in acute hyperkalemia is complicated by a variable onset of action (2-6 hrs), a variable duration of action (6-24 hrs), lack of robust efficacy data, and concerns for serious adverse events. [1] [2] [3] Efficacy data for acute hyperkalemia are elusive and placebo-controlled interventions unlikely given ethical considerations. In comparison with SPS, our results indicate that ZS-9 has a potential role in the management of acute hyperkalemia given its 1-hour onset of action, robust efficacy data (Figure 3) , and mild adverse effect profile. On the other side of the coin, short trial durations of 2-28 days limit the ability to use ZS-9 in the long-term setting as is the case with patiromer. An 11-month extension to the hyperkalemia randomized intervention multidose ZS-9 maintenance study (HARMONIZE trial) was recently completed and will provide critical longterm data (NCT02107092, clinicaltrials.gov) as will an additional 12-month trial that is currently underway (NCT02163499, clinicaltrials.gov).
ZS-9 was associated with less frequent GI effects compared with patiromer with rates similar to those observed in placebo groups. This difference may be due to the inorganic lattice structure of ZS-9 that does not swell in gastric juices. 33 In addition, no cases of hypomagnesemia were reported in patients receiving ZS-9, and hypokalemia occurred less often. These differences are likely the result of the higher specificity of ZS-9 for the potassium ion compared with patiromer that displays nonspecific binding and can also bind magnesium. A few adverse effects, such as urinary tract infections, QTc interval prolongation, and edema, occurred exclusively in patients receiving ZS-9. Although QTc interval prolongation is a concerning adverse event, it is an expected physiologic effect of quickly lowering the extracellular potassium concentration. In addition, the changes observed were clinically insignificant (0.03-10.3 msec increase), and no differences were observed in the rate of arrhythmias between the ZS-9 and placebo groups. 19 Some concern has surrounded ZS-9 due to the sodium content of a 10-g dose (~1000 mg) leading to edema and/or hypertension. It is important to note that SPS contains 1500 mg of sodium per 15 g dose and that rates of edema and hypertension were low in ZS-9 trials (less than 1%).
The clinical trials for ZS-9 and patiromer included many patients with CKD, heart failure, and diabetes mellitus. No discernable differences were found in the safety or efficacy of patiromer and ZS-9 for these subgroups. Nonetheless, certain special populations at high risk of hyperkalemia or complications from treatment were largely excluded from trials and should be the focus of further research. These include patients on dialysis, renal transplant recipients, patients Baseline potassium concentration was from the initial phase for trials with multiple phases. AMETHYST-DN = patiromer in the treatment of hyperkalemia in patients with hypertension and diabetic nephropathy; HARMONIZE = Hyperkalemia Randomized Intervention Multidose ZS-9 Maintenance study; NA = not applicable; OPAL-HK = two-part single-blind phase III study evaluating the efficacy and safety of patiromer for the treatment of hyperkalemia; PEARL-HF = evaluation of patiromer in heart failure patients; SD = standard deviation; ZS-9 = sodium zirconium cyclosilicate.
with GI disorders, and postsurgical patients. Practitioners should be highly cautious about using ZS-9 or patiromer in these patients given the lack of safety and efficacy data. SPS has been the lone treatment option for hyperkalemia for more than 50 years. Use of SPS is fraught with untoward GI effects ranging from nausea and diarrhea to mucosal damage and intestinal necrosis. [4] [5] [6] SPS can also cause hypernatremia, hypocalcemia, and hypomagnesemia. The initial study of SPS in 1961 included 32 hyperkalemic patients with no control group. 34 A recent randomized placebo-controlled study in 33 CKD patients with mild hyperkalemia demonstrated efficacy of SPS with a mean serum potassium reduction of À1.04 mEq/L (95% CI À0.71 to À1.37 mEq/L) after 7 days of treatment compared with placebo. 8 However, the small sample size, mild degree of hyperkalemia, and short duration leave many unanswered questions. With unknown efficacy and well-known toxicities, clinicians have struggled to manage hyperkalemia with SPS. 2, 7 Compared with SPS, patiromer appears to have improved long-term tolerability with no reports of serious GI-adverse effects but a longer onset of action and concern for drug-drug interactions. Also compared with SPS, ZS-9 has a more rapid onset of effect and very few adverse effects, but long-term data are limited. Both patiromer and ZS-9 have multiple well-designed randomized controlled trials supporting their efficacy for which SPS is lacking.
Our study has several possible limitations. Publication bias is always a consideration in systematic reviews, but that is minimized with this study given our focus on phase II and III clinical trials. An Egger test was not performed due to the small number of trials included in the meta-analysis. 35 The quality of studies was adequate, but a number of them included open-label phases that introduce a high risk of bias. These initial treatment phases are unlikely to be avoided given the ethical concern of giving a placebo to a patient with hyperkalemia. In addition, the outcome of change in potassium concentration is standardized and objective, mitigating the risk of bias in outcome assessment. There was significant heterogeneity (I 2 higher than 75%) for each end point assessed by meta-analysis, and therefore a random-effects meta-analysis was applied. 24, 36, 37 This heterogeneity is likely derived from the bias as discussed earlier and the differences in study population that included a variety of disease states, geographic regions, baseline potassium concentrations, and doses of the agents used.
Another limitation is the lack of clinical outcomes assessed in the phase II and III clinical trials. Future trials should include outcomes such as hyperkalemia-associated arrhythmias, morbidity, and mortality.
Despite these limitations, this study has several implications. This meta-analysis of well-conducted phase II and III clinical trials provides a higher level of evidence than individual clinical trials by providing an estimate of the overall pooled effect size with optimal accuracy and precision. 36, 38 This meta-analysis delineates ZS-9 as a potential new agent for treatment of acute hyperkalemia when compared with patiromer given its 1-hour onset of effect and data from the subgroup study of severe hyperkalemia. 27 However, baseline potassium concentrations were mildly elevated and similar between patiromer (5.31 mEq/L) and ZS-9 (5.35 mEq/L) trials and do not necessitate acute treatment. A randomized controlled trial directly comparing ZS-9, patiromer, and SPS would be necessary to test this hypothesis. Precise effect estimates are provided for clinically relevant time periods (e.g., 1 hr, 2 days, 3 days, and 4 wks) and are stratified by varying degrees of hyperkalemia and doses of each agent. These results are corroborated by the fixed-effects sensitivity analysis. The point estimates were similar between the random-effects and fixed-effects models indicating a robust primary analysis. Lastly, this study identifies several areas for further research: postmarketing surveillance for rare but serious GI-adverse effects, once/day patiromer dose response, long-term efficacy data for ZS-9, and use of these agents in special populations.
Conclusion
This study provides precise effect estimates for the potassium reduction of patiromer sorbitex calcium and sodium zirconium cyclosilicate. These agents are a significant advancement in our armamentarium for the treatment of hyperkalemia. Compared with SPS, these drugs are more selective for the potassium ion, 33 exhibit an improved adverse event profile, and result in a more consistent potassium-lowering effect. Differences between patiromer and ZS-9 include time to onset of effect, adverse event profiles, and drug interactions. Although the clinical niche for these drugs remains to be seen, patiromer appears likely to play more of a role in the chronic management of hyperkalemia, whereas ZS-9 may be better suited for acute therapy.
